MCID: NRG002
MIFTS: 54

Neurogenic Bladder

Categories: Nephrological diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Bladder

MalaCards integrated aliases for Neurogenic Bladder:

Name: Neurogenic Bladder 12 29 6 15
Neurogenic Dysfunction of the Urinary Bladder 12
Neurogenic Urinary Bladder Disorder 12
Urinary Bladder, Neurogenic 43
Neurogenic Urinary Bladder 71
Neuropathic Bladder 12
Bladder Neurogenic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:12143
ICD9CM 34 596.54
MeSH 43 D001750
NCIt 49 C79696
SNOMED-CT 67 23201000
UMLS 71 C0005697

Summaries for Neurogenic Bladder

MalaCards based summary : Neurogenic Bladder, also known as neurogenic dysfunction of the urinary bladder, is related to lethal congenital contracture syndrome 2 and detrusor sphincter dyssynergia, and has symptoms including seizures, vertigo and pain. An important gene associated with Neurogenic Bladder is EBF3 (EBF Transcription Factor 3), and among its related pathways/superpathways are Calcium signaling pathway and Taste transduction. The drugs Lidocaine and Silodosin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, kidney and prostate, and related phenotypes are homeostasis/metabolism and behavior/neurological

Wikipedia : 74 Neurogenic bladder dysfunction, or neurogenic bladder, refers to urinary bladder problems due to disease... more...

Related Diseases for Neurogenic Bladder

Diseases related to Neurogenic Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 lethal congenital contracture syndrome 2 32.5 PIP5K1C ERBB3
2 detrusor sphincter dyssynergia 30.9 P2RX3 P2RX2 NGF
3 low compliance bladder 30.8 P2RX3 NGF CHRM2
4 cystitis 29.9 UPK3A TACR1 P2RX3 NGF
5 radiation cystitis 29.8 UPK3A KLK3
6 chronic cystitis 29.7 UPK3A P2RX3 NGF
7 interstitial cystitis 29.6 UPK3A TACR1 P2RX3 NGF
8 hinman syndrome 11.9
9 urofacial syndrome 1 11.8
10 sacral defect with anterior meningocele 11.6
11 polyglucosan body neuropathy, adult form 11.4
12 adult polyglucosan body disease 11.4
13 lateral meningocele syndrome 11.3
14 lethal congenital contracture syndrome 3 11.3
15 peroxisome biogenesis disorder 10b 11.3
16 leukodystrophy, progressive, early childhood-onset 11.3
17 giant axonal neuropathy 11.3
18 cog5-congenital disorder of glycosylation 11.3
19 spinal cord injury 11.0
20 acute cystitis 10.8
21 myelomeningocele 10.8
22 neural tube defects 10.8
23 vesicoureteral reflux 1 10.8
24 hydronephrosis 10.7
25 bacteriuria 10.6
26 pyelonephritis 10.5
27 bladder disease 10.5
28 paraplegia 10.4
29 constipation 10.4
30 spasticity 10.4
31 multiple sclerosis 10.4
32 pyuria 10.3
33 bladder cancer 10.3
34 herpes zoster 10.3
35 prostatic hypertrophy 10.3
36 quadriplegia 10.3
37 urinary tract obstruction 10.3
38 myelitis 10.3
39 lipomatosis, multiple 10.3
40 pleomorphic lipoma 10.3
41 impotence 10.3
42 kidney disease 10.3
43 neuropathy 10.3
44 end stage renal failure 10.2
45 spinal shock 10.2
46 prostatic hyperplasia, benign 10.2
47 hydrocephalus 10.2
48 urethral stricture 10.2
49 cerebral palsy 10.2
50 prostatic adenoma 10.2

Comorbidity relations with Neurogenic Bladder via Phenotypic Disease Network (PDN): (show all 27)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Bladder Neck Obstruction Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Hypertension, Essential
Hypothyroidism Multiple Sclerosis
Osteoporosis Paralytic Ileus
Paraplegia Parkinson Disease, Late-Onset
Peripheral Vascular Disease Prostatic Hypertrophy
Protein-Energy Malnutrition Schizophreniform Disorder
Swallowing Disorders Transient Cerebral Ischemia
Urethral Stricture

Graphical network of the top 20 diseases related to Neurogenic Bladder:



Diseases related to Neurogenic Bladder

Symptoms & Phenotypes for Neurogenic Bladder

UMLS symptoms related to Neurogenic Bladder:


seizures, vertigo, pain, dysuria, meningism, reflex, abnormal, urgency of micturition, neurobehavioral manifestations, neuromuscular manifestations

MGI Mouse Phenotypes related to Neurogenic Bladder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 ACER3 CACNA1A CHRM2 ERBB3 GBE1 HPSE2
2 behavior/neurological MP:0005386 10.06 ACER3 CACNA1A CHRM2 COL6A2 ERBB3 GBE1
3 integument MP:0010771 9.76 CACNA1A CHRM2 ERBB3 NGF P2RX3 PEX3
4 nervous system MP:0003631 9.7 ACER3 CACNA1A CHRM2 EBF3 ERBB3 GBE1
5 respiratory system MP:0005388 9.17 CACNA1A CHRM2 ERBB3 GBE1 P2RX2 P2RX3

Drugs & Therapeutics for Neurogenic Bladder

Drugs for Neurogenic Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Silodosin Approved Phase 4 160970-54-7
3
Belladonna Approved, Experimental Phase 4
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Mirabegron Approved Phase 4 223673-61-8 9865528
6
Cefixime Approved, Investigational Phase 4 79350-37-1 54362 5362065
7
Fosfomycin Approved Phase 4 23155-02-4 446987
8
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
11
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
12
Methenamine Approved, Vet_approved Phase 4 100-97-0 4101
13
Fidaxomicin Approved Phase 4 873857-62-6
14
Vancomycin Approved Phase 4 1404-90-6 441141 14969
15 Neurotransmitter Agents Phase 4
16 Autonomic Agents Phase 4
17 Cholinergic Agents Phase 4
18 Cholinergic Antagonists Phase 4
19 Adrenergic Agents Phase 4
20 Narcotics Phase 4
21 Analgesics, Opioid Phase 4
22 Opiate Alkaloids Phase 4
23 Central Nervous System Depressants Phase 4
24 Analgesics Phase 4
25 Adrenergic Agonists Phase 4
26 Adrenergic beta-3 Receptor Agonists Phase 4
27 Adrenergic beta-Agonists Phase 4
28 Solifenacin succinate Phase 4 242478-38-2
29 penicillins Phase 4
30 Muscarinic Antagonists Phase 4
31 Parasympatholytics Phase 4
32 Mandelic Acids Phase 4
33 Renal Agents Phase 4
34 Anti-Infective Agents, Urinary Phase 4
35 Antibiotics, Antitubercular Phase 4
36 Methenamine mandelate Phase 4
37 Methenamine hippurate Phase 4
38 Bifidobacterium Phase 4
39 Cola Phase 4
40 Anti-Infective Agents Phase 4
41 Anti-Bacterial Agents Phase 4
42
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
43
Tamsulosin Approved, Investigational Phase 2, Phase 3 106133-20-4 129211
44
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
45
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
46
Ofloxacin Approved Phase 3 82419-36-1 4583
47
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
48 Cranberry Approved, Investigational Phase 3
49
Fesoterodine Approved Phase 3 286930-03-8, 286930-02-7 6918558
50
Midazolam Approved, Illicit Phase 3 59467-70-8 4192

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
2 Randomized Placebo-Controlled Trial of Gentamicin Bladder Instillation for the Prevention of Urinary Tract Infection in Adults at High Risk for Cystitis Due to Intermittent Catheterization Unknown status NCT01884467 Phase 4 Gentamicin;Placebo
3 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Unknown status NCT02298660 Phase 4 BOTOX
4 A 12-week, Open-label, Multi-center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder Completed NCT01228370 Phase 4 silodosin
5 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial) Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
6 Quality of Life Intermittent Catheter Study - A Prospective, Randomized, Cross-over, Multicenter Study Comparing Quality of Life Using Compact Versus Standard Urinary Intermittent Catheters Completed NCT01523743 Phase 4
7 A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
8 A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
9 Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy Completed NCT01421719 Phase 4 Cystoscopic injection of Botox into the urinary bladder
10 A Prospective, Randomized, Parallel-group, Multi-center Study to Compare the Occurrence of Urinary Tract Infections in Patients With Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters. Completed NCT00318591 Phase 4
11 A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury Completed NCT00224029 Phase 4 Oxybutynin transdermal system
12 Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome (Cts): A Randomized, Placebo-Controlled Trial With Secondary Bayesian Modification Completed NCT00277563 Phase 4
13 The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1 Completed NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
14 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
15 A Two-part, Multicenter, Dose-titration Study Evaluating Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for Treatment of Detrusor Overactivity Associated Neurological Condition in Pediatric Patients Recruiting NCT01192568 Phase 4 Oxybutynin
16 Use of Novel Human Milk Prebiotics to Improve the Quality of Life for Spinal Cord Injury Patients With Bowel and Bladder Dysfunction Not yet recruiting NCT03987126 Phase 4
17 The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing Due to New Episodes of Urinary Tract Infections (UTI) in Elderly Women With Recurrent UTI - a Triple- Blinded, Randomized Placebo-controlled Phase IV Study Not yet recruiting NCT04077580 Phase 4 Methenamine Hippurate 1000 MG
18 Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
19 Antiseptic-coated Intermittent Urinary Catheter: Efficacy and Feasibility of Neurogenic Bladder Management and Prevention of Catheter-associated Urinary Tract Infections in Children Unknown status NCT02697162 Phase 2, Phase 3 Octenidine chloride
20 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
21 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
22 A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04) Unknown status NCT01050114 Phase 3 onaBoNT-A;Oxybutynin ER
23 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
24 A Phase IIb/III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Dose Ranging Study of Tamsulosin Hydrochloride (Low, Medium and High Dose) as Treatment in Children With Neuropathic Bladder for Three Months Completed NCT00796614 Phase 2, Phase 3 tamsulosin hydrochloride;Placebo
25 A Pilot Study Comparing the Effects of Botulinum Toxin A and Standard Oxybutynin Therapy as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Completed NCT01716624 Phase 3 Oxybutynin;Botulinum Toxin A injection
26 Four-week, Open-label, Multicenter, Randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety, Tolerability and the Effects on Leak Point Pressure of Two Oral Doses of Alfuzosin (0.1 mg/kg/Day; 0.2 mg/kg/Day) in Children and Adolescents 2 to 16 Years-of-age With Elevated Detrusor Leak-point Pressure of Neuropathic Etiology Completed NCT00629720 Phase 3 alfuzosin (SL770499)
27 12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension Completed NCT00549939 Phase 3 Alfuzosin;Placebo
28 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed NCT01600716 Phase 3 Placebo (Normal Saline)
29 12-week, Multicenter, Open-label, Non-comparative Study to Investigate Pharmacodynamic and Safety of Alfuzosin 0.2 mg/kg/Day in the Treatment of Children and Adolescents 2 - 16 Years of Age With Hydronephrosis Associated With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension Completed NCT00576823 Phase 3 Alfuzosin
30 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
31 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
32 Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients. Completed NCT00280592 Phase 3 Cranberry;Placebo
33 A 24-WEEK RANDOMIZED, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) Recruiting NCT01557244 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine PR 8 mg;Oxybutynin;Fesoterodine PR;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
34 Oxybutynin for Post-surgical Bladder Pain and Urgency Recruiting NCT03952299 Phase 3 Oxybutynin Transdermal Patch;Oral Oxybutynin
35 LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) WHO HAVE COMPLETED 24 WEEKS TREATMENT IN STUDY A0221047 Recruiting NCT02501928 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
36 Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS) Recruiting NCT03774407 Phase 2, Phase 3 vaginal estriol
37 The Effect of Gentamicin Intravesical Installations on Decreasing Urinary Tract Infections in Patients With Neurogenic Bladder After Spinal Cord Injury: A Clinical Trial Suspended NCT03503513 Phase 2, Phase 3 Gentamicin Sulfate;Saline
38 A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients Terminated NCT02044510 Phase 2, Phase 3 Mirabegron;Placebo
39 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
40 Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction Unknown status NCT00602186 Phase 1, Phase 2 tamsolusin;prazosin
41 Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study Unknown status NCT02591901 Phase 2 Uro vaxom
42 A Clinical Trial to Determine the Extent to Which Probiotic Therapy Reduces Side Effects of Antibiotic Prophylaxis in Pediatric Neurogenic Bladder Patients With a History of Recurrent Urinary Tract Infections Unknown status NCT02044965 Phase 1, Phase 2 Probiotic
43 An Uncontrolled, Open-label, Titration, Long-term Safety (up to 12 Months) and Efficacy Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder, With a Randomized Pharmacokinetic Sub-study Investigating Low, Medium and High Dose Ranges. Completed NCT00340704 Phase 2 tamsulosin hydrochloride
44 Self-management of Urine Flow in Long-term Urinary Catheter Users Completed NCT00883220 Phase 2
45 Multifaceted Treatment of Catheter-related Urinary Tract Infection Completed NCT00732238 Phase 2
46 A Multicenter, Double-blind, Crossover Design, Pilot Study to Evaluate the Effect of NVC-422 Catheter Irrigation on Urinary Catheter Patency Completed NCT01243125 Phase 2 NVC-422, 0.2%;Sterile normal saline, 0.9%
47 Lumbar to Sacral Ventral Nerve Re-Routing Completed NCT00378664 Phase 2
48 A Treatment Trial of Triheptanoin in Patients With Adult Polyglucosan Body Disease - A Randomized Controlled Study Completed NCT00947960 Phase 2 Triheptanoin
49 UTI Prophylaxis Using Bacterial Interference Following SCI Completed NCT00037921 Phase 2
50 Comparison of the Therapeutic Effects of Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome Completed NCT01657409 Phase 2 BoNT-A (10 injection);BoNT-A (20 injection);BoNT-A (40 injection)

Search NIH Clinical Center for Neurogenic Bladder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Baclofen
Bethanechol
Bethanechol Chloride
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
oxybutynin
Oxybutynin chloride

Cochrane evidence based reviews: urinary bladder, neurogenic

Genetic Tests for Neurogenic Bladder

Genetic tests related to Neurogenic Bladder:

# Genetic test Affiliating Genes
1 Neurogenic Bladder 29

Anatomical Context for Neurogenic Bladder

MalaCards organs/tissues related to Neurogenic Bladder:

40
Spinal Cord, Kidney, Prostate, Brain, Testes, Colon, Bone

Publications for Neurogenic Bladder

Articles related to Neurogenic Bladder:

(show top 50) (show all 4014)
# Title Authors PMID Year
1
Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. 54 61
12783571 2003
2
Physiology and Pathophysiology of the Autonomic Nervous System. 61
31996619 2020
3
A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. 61
32017693 2020
4
Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A. 61
31518199 2020
5
Risk factors for febrile urinary tract infections in the first year after pediatric renal transplantation. 61
31880402 2020
6
Long-term Outcome of Renal Transplantation in Patients with Congenital Lower Urinary Tract Malformations: A Multicenter Study. 61
30964838 2020
7
Concurrent urinary and bowel diversion: Surgical modification with sigmoid colon that avoids a bowel anastomosis. 61
31851467 2020
8
EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. 61
31724222 2020
9
Efficiency and Safety of the Sting Operation on Kidney Transplanted Patients with Symptomatic Vesicoureteral Reflux and Neurogenic Bladder Dysfunction. 61
31901322 2020
10
Neurogenic bladder monitoring using the cystomanometer and cystoelastometer. 61
32005418 2020
11
Dialysis in Pregnancy: Role of the Underlying Cause of Renal Failure on Peripartum Outcomes. 61
31910463 2020
12
Cauda equina syndrome: false-positive diagnosis of neurogenic bladder can be reduced by multichannel urodynamic study. 61
31907657 2020
13
Pediatric Neurogenic Bladder and Bowel Dysfunction: Will My Child Ever Be out of Diapers? 61
31982364 2020
14
The effects of botulinum toxin injection on urodynamic changes in pediatric population with neurospastic bladder: First trial in Iran. 61
32019705 2020
15
Use of oral third generation cephalosporins and quinolones and occurrence of antibiotic-resistant strains in the neurogenic bladder (NB) outpatient setting: a retrospective chart audit. 61
31965059 2020
16
Reasons for cessation of clean intermittent catheterization after spinal cord injury: Results from the Neurogenic Bladder Research Group spinal cord injury registry. 61
31578784 2020
17
Different types of acupuncture and moxibustion therapy for neurogenic bladder after spinal cord injury: A systematic review and network meta-analysis study protocol. 61
31895798 2020
18
Implantation of Sacral Nerve Stimulator Without Rhizotomy for Neurogenic Bladder in Patient With Spinal Cord Injury: 2-Dimensional Operative Video. 61
31980830 2020
19
Urodynamic Parameters in Spinal Cord Injury-Induced Neurogenic Bladder Rats after Stem Cell Transplantation: A Narrative Review. 61
32038054 2020
20
A rare case of emphysematous spongiositis following urethral catheterization: A case report. 61
31641613 2020
21
Risk factors for quinolone-resistant Escherichia coli infection: a systematic review and meta-analysis. 61
31938541 2020
22
Kidney transplantation using a colon pouch (Mainz pouch III): a case report. 61
31894920 2019
23
The Stockholm Spinal Cord Uro Study: 1. Basic characteristics and problem inventory. 61
31630596 2019
24
[A Case of Neurofibromatosis Type 1 Presenting Voiding Symptoms Caused by Giant Bladder Diverticulum]. 61
31933336 2019
25
Weekly sequential antibioprophylaxis for recurrent UTI among patients with neurogenic bladder: a randomized controlled trial. 61
31867616 2019
26
Create a predictive model for neurogenic bladder patients: upper urinary tract damage predictive nomogram. 61
31401918 2019
27
The use of mirabegron in neurogenic bladder: a systematic review. 61
31802206 2019
28
Evaluation and Long-term Management of Neurogenic Bladder in Spinal Dysraphism. 61
31792158 2019
29
[Acute flaccid paralysis related to enterovirus with complete resolution of the neurological symptoms. A pediatric case report]. 61
31758907 2019
30
The impact of catheter-based bladder drainage method on urinary tract infection risk in spinal cord injury and neurogenic bladder: A systematic review. 61
31845396 2019
31
Efficacy and security of continent catheterizable channels at short and middle term for adult neurogenic bladder dysfunction. 61
31540862 2019
32
EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part II operative management. 61
31794087 2019
33
Transureteroureterostomy as an adjunctive antireflux procedure in children undergoing bladder augmentation for neurogenic bladder with major reflux. 61
31932241 2019
34
Inappropriate initial urinary catheter placement among older Chinese hospital inpatients: An observational study. 61
31793146 2019
35
Clam augmentation enterocystoplasty as management of urge urinary incontinence and reduced bladder capacity. 61
31757178 2019
36
One-Step Reconstruction with a Novel Suspended, Modular, and 3D-Printed Total Sacral Implant Resection of Sacral Giant Cell Tumor with Preservation of Bilateral S1-3 Nerve Roots via a Posterior-Only Approach. 61
31854115 2019
37
Immediate effect of transcutaneous electrical nerve stimulation on urodynamic parameters of children with myelomeningocele. 61
31486143 2019
38
Albuminuria in Pediatric Neurogenic Bladder: Identifying an Earlier Marker of Renal Disease. 61
31454657 2019
39
Long-term follow-up of neurogenic bladder patients after bladder augmentation with small intestinal submucosa. 61
31712957 2019
40
Leukoencephalopathy With Predominant Infratentorial Involvement Caused by a Novel ABCD1 Mutation: Does the Spinocerebellar Variant of Adrenoleukodystrophy Exist? 61
31688712 2019
41
Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. 61
31684987 2019
42
Neurogenic bladder associated with xeroderma pigmentosum type A: A case report and literature review. 61
31467858 2019
43
Robotic Bladder Neck Reconstruction With Mitrofanoff Appendicovesicostomy in a Neurogenic Bladder Patient. 61
31790786 2019
44
Effect of intravesical botulinum toxin injection on symptoms of autonomic dysreflexia in a patient with chronic spinal cord injury: a case report. 61
28486884 2019
45
Transcranial magnetic stimulation and bladder function: A systematic review. 61
31541980 2019
46
[Effect of SU Jia-fu's Wenjing Tongdu external treatment combined with long-snake moxibustion at governor vessel on urodynamic for neurogenic bladder after spinal cord injury]. 61
31724353 2019
47
Unexpected foreign body in the bladder of a spinal cord injured patient: A case report. 61
30557084 2019
48
Reviewing the prognostic factors in myelomeningocele. 61
31574474 2019
49
Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer. 61
31351675 2019
50
Is baseline routine renal ultrasound indicated for all MS patients? 61
31611266 2019

Variations for Neurogenic Bladder

ClinVar genetic disease variations for Neurogenic Bladder:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EBF3 NM_001005463.3(EBF3):c.512G>A (p.Gly171Asp)SNV Pathogenic 375375 rs1057519437 10:131755564-131755564 10:129957300-129957300
2 CACNA1A NM_001127221.1(CACNA1A):c.6128C>T (p.Thr2043Met)SNV Uncertain significance 386521 rs563345694 19:13323262-13323262 19:13212448-13212448
3 COL6A2 NM_001849.3(COL6A2):c.2008A>G (p.Thr670Ala)SNV Uncertain significance 598977 rs753298014 21:47545737-47545737 21:46125823-46125823

Expression for Neurogenic Bladder

Search GEO for disease gene expression data for Neurogenic Bladder.

Pathways for Neurogenic Bladder

Pathways related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.46 TACR1 P2RX3 P2RX2 P2RX1 ERBB3 CHRM2
2
Show member pathways
11.22 P2RX3 P2RX2 CACNA1A

GO Terms for Neurogenic Bladder

Cellular components related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of nuclear inner membrane GO:0005639 8.8 P2RX3 P2RX2 P2RX1

Biological processes related to Neurogenic Bladder according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.76 P2RX3 P2RX2 CHRM2 CACNA1A
2 response to organic substance GO:0010033 9.7 P2RX3 P2RX2 P2RX1
3 modulation of chemical synaptic transmission GO:0050804 9.65 P2RX3 NGF CACNA1A
4 excitatory postsynaptic potential GO:0060079 9.58 P2RX3 P2RX2 P2RX1
5 response to pain GO:0048265 9.57 TACR1 CACNA1A
6 regulation of smooth muscle contraction GO:0006940 9.56 P2RX1 CHRM2
7 positive regulation of calcium-mediated signaling GO:0050850 9.55 P2RX3 P2RX2
8 regulation of presynaptic cytosolic calcium ion concentration GO:0099509 9.54 P2RX1 CACNA1A
9 positive regulation of calcium ion transport into cytosol GO:0010524 9.51 P2RX3 P2RX2
10 cation transmembrane transport GO:0098655 9.5 P2RX3 P2RX2 P2RX1
11 response to carbohydrate GO:0009743 9.49 P2RX3 P2RX2
12 peristalsis GO:0030432 9.43 P2RX3 P2RX2
13 neuromuscular synaptic transmission GO:0007274 9.43 P2RX3 P2RX2 CACNA1A
14 urinary bladder smooth muscle contraction GO:0014832 9.37 P2RX3 P2RX2
15 response to ATP GO:0033198 9.33 P2RX3 P2RX2 P2RX1
16 behavioral response to pain GO:0048266 9.13 P2RX3 P2RX2 CACNA1A
17 purinergic nucleotide receptor signaling pathway GO:0035590 8.8 P2RX3 P2RX2 P2RX1

Molecular functions related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.46 P2RX3 P2RX2 P2RX1 CACNA1A
2 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides GO:0016811 9.26 KLK3 ACER3
3 extracellularly ATP-gated cation channel activity GO:0004931 9.13 P2RX3 P2RX2 P2RX1
4 purinergic nucleotide receptor activity GO:0001614 8.8 P2RX3 P2RX2 P2RX1

Sources for Neurogenic Bladder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....